2-(3-isopropyl-ureido)-5-trifluoromethyl-benzoic acid | 439151-92-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-isopropyl-ureido)-5-trifluoromethyl-benzoic acid
• 英文别名: 2-(propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzoic acid
• CAS: 439151-92-5
• 化学式: C₁₂H₁₃F₃N₂O₃
• 分子量: 290.242
• InChiKey: IQQWNWAUCGFKMA-UHFFFAOYSA-N

物化性质

• 沸点：
  358.7±42.0 °C(Predicted)
• 密度：
  1.377±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  78.4
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(3-isopropyl-ureido)-5-trifluoromethyl-benzoic acid 生成 4-endo-5-{3-[2-(3-isopropylureido)-5-trifluoromethyl-benzoylamino]-2-oxopyrrolidin-1-yl}-4-propyloctahydro-cyclopenta[c]pyrrole-2-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity

  摘要：

  本申请描述了公式(I)的MCP-1调节剂，或其立体异构体或药学上可接受的盐，其中X、Z、a、b、c、d、键g、n、s、R1、R2、R4、R5、R10、R12和R13如上所定义。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。

  公开号：

  US20050192276A1
• 作为产物：
  描述：

  4-(tert-butyl)-2-(hexa-1,5-dien-2-yl)-1-(4-methyl-2-methylenepentyl)benzene 在 四氢吡咯 、 四(三苯基膦)钯 作用下， 以 乙腈 为溶剂， 生成 2-(3-isopropyl-ureido)-5-trifluoromethyl-benzoic acid
  参考文献：
  名称：

  Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists

  摘要：

  Potent sulfone-containing di- and trisubstituted cyclohexanes were synthesized and evaluated as CC chemokine receptor 2 (CCR2) antagonists. This led to the trisubstituted derivative 54, which exhibited excellent binding (CCR2 IC50 = 1.3 nM) and functional antagonism (calcium flux IC50 = 0.5 nM and chemotaxis IC50 = 0.2 nM). The superiority of the trisubstituted scaffold was rationalized to be the result of a conformational rigidification, which provided insight into the bioactive conformation of this chemotype. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.041

文献信息

• Cyclic derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054627A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

  当前申请描述了MCP-1的调节剂，其化学公式为(I):或其药用可接受的盐形式，用于治疗类风湿性关节炎、多发性硬化症、动脉粥样硬化和哮喘。
• Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054626A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

  本申请描述了MCP-1的调节剂，化学式为(I)：或其药用可接受的盐形式，用于预防哮喘、多发性硬化症、动脉粥样硬化和类风湿性关节炎。
• Diamines as modulators of chemokine receptor activity
  申请人：——

  公开号：US20030060459A1

  公开（公告）日：2003-03-27

  The present application describes modulators of MCP-1 of formula (I): 1 or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

  本申请描述了公式(I)的MCP-1调节剂或其药用盐形式，用于预防哮喘、多发性硬化症、动脉粥样硬化和类风湿性关节炎。
• Cyclic derivatives as modulators of chemokine receptors activity
  申请人：Cherney J. Robert

  公开号：US20060135503A1

  公开（公告）日：2006-06-22

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ transplantation, and cancer.

  本申请描述了MCP-1调节剂的化学式(I)或其药学上可接受的盐形式，可用于预防类风湿性关节炎、多发性硬化症、动脉粥样硬化、哮喘、再狭窄、器官移植和癌症。
• CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Carter Percy H.

  公开号：US20090124668A1

  公开（公告）日：2009-05-14

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

  本申请描述了 MCP-1 的调节剂，其化学式为 (I) 或其药学上可接受的盐形式，适用于治疗类风湿性关节炎、多发性硬化症、动脉粥样硬化和哮喘。